drugset
Drugs / Dapiglutide
last change Feb 2026 re-read 3 minutes ago

Dapiglutide

Protein / enzyme biologic

Developed for
obesity disorder
Investigated by
Profil Institute for Metabolic Research GmbH · Zealand Pharma

Trials 1

today NCT06758583 · Ph 1
20252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT06758583 Dec 2024 → Apr 2025 — Zealand Pharma Completed No outcome recorded
Comparator or background therapy1 trial
Phase 2 NCT05788601 Comparator Apr 2023 → Apr 2024 overdue obesity disorder University Hospital, Gentofte, Copenhagen Active not recruiting No outcome recorded

Press releases naming this drug 5 releases

DateIssuerRelease
2025-06-18 Zealand Pharma Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide zealandpharma.com ↗
2024-09-09 Zealand Pharma Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide zealandpharma.com ↗
2024-05-23 Zealand Pharma Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide zealandpharma.com ↗
2022-06-06 Zealand Pharma Zealand Pharma Presents Data from Phase 1 Trial of Dapiglutide at the 82nd Annual American Diabetes Association Scientific Sessions and Announces Dapiglutide to Move into Phase 2 Trial for Obesity zealandpharma.com ↗
2022-05-31 Zealand Pharma Zealand Pharma Announces Multiple Presentations at the 82nd Annual American Diabetes Association Scientific Sessions, Including Initial Clinical Data on GLP-1/GLP-2 Dual Agonist Dapiglutide zealandpharma.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as Dapiglutide ClinicalTrials.gov intervention name — accepted as the source's own label NCT05788601 ↗
1

NCT06758583 ↗
Action Activate “Dapiglutide, a dual glucagon-like peptide (GLP)-1 and GLP-2 receptor agonist” PMID 41768273 ↗ Feb 2026
Modality Protein / enzyme biologic — CHEMBL5314980 ↗
Route Subcutaneous “once-weekly subcutaneous dapiglutide (4 or 6 mg)” PMID 41768273 ↗ Feb 2026